Investing-News.Com
Information for Investors

DYAX CORP, (DYAX) Stock Ratings - Investing-News.Com
 

 Home   Market News   Analysis   Commentary   Education   Tools   Weekly Report 

Internet Search   Stock Search
   

 

DYAX CORP, (DYAX) Stock Rating Learn More

Our Overall Rating on Dyax Corp,  DYAX is BUY
StockPickReport.Com research suggests DYAX's price will move higher than the "open price" the day this rating was initiated.

This analysis is based on short-term stochastic and "relative strength" indicators.

With StockPickReport.Com's "Buy" rating, stochastic and "relative strength" numbers may agree, but not in all cases.

Investors, traders, and other market participants may find this a good opportunity to buy DYAX, "buy calls", or "sell puts".

This may also be an opportunity to raise targets and stop/losses to allow for potential gains (although those gains may not be as signficant as gains experienced in conjunction with a "Strong Buy" rating).

Trading volume seems to be falling and DYAX's closing price moved up during the week before this rating was initiated.

Our BUY Rating on DYAX was issued on 03/25/08

DYAX CORP Technical Rating



Ratings Provided by Stock-Letter-Daily.Com

Rate Any Stock
(enter symbol and click)

Stock Rating Definitions

Stock Ratings Home

Sponsored Links:

Software Forces DYAX CORP Investors To Buy Low and Sell High The Position Cost Averaging Stock Investing Systems helps LONG-TERM investors in DYAX CORP buy low and sell high every time guaranteed. Click Here To Learn More

We Give Precision Entry & Exit Points on DYAX CORP. This software is specially designed to give precision entry and exit points on DYAX CORP, or any other stock you choose.
Click Here to learn how to take control of your trading.

How To Know When DYAX CORP Beats The Street. New Software Offers "One-Click" Stock Picks. The StockPickerRT will pick stocks for you every trading day based on earnings, volume & momentum. Maybe even DYAX CORP, if they make the cut.
Click Here & Learn To
Pick Winners In An Uncertain Market



Related Searches: forex trading platform  www.rband.com 

Research Home


Article Search


Advanced Search

StreetInsider Alerts

Latest Headlines

Dyax drug candidate gets FDA priority review (AP)

UPDATE - Dyax's genetic disease drug granted fast review (at Reuters)

InPlay: Dyax announces the FDA accepts filing and grants priority review for DX-88 for hereditary angioedema (Briefing.com)

FDA Accepts Filing and Grants Priority Review for DX-88 for Hereditary Angioedema (Business Wire)

Dyax Corp. to Present at the Lazard Capital Markets Healthcare Conference (Business Wire)

First-Ever Study Conducted Demonstrating Economic, Individual, and Societal Burden of Hereditary Angioedema (Business Wire)

Dyax Corp. to Present at the Credit Suisse Healthcare Conference (Business Wire)

Dyax Corp. to Present at the Rodman & Renshaw Healthcare Conference (Business Wire)

Dyax Corporation Q3 2008 Earnings Call Transcript (at Seeking Alpha)

DYAX CORP Financials (EDGAR Online Financials)

  Place Our Content On Your Site!  rss Powered By The Investing System Network
© 2006 Investing-News.Com, All Rights Reserved.